𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-α in soft tissue sarcoma bearing rats

✍ Scribed by Alexander H. van der Veen; Alexander M. M. Eggermont; Ann L. B. Seynhaeve; Sandra T. van Tiel; Timo L. M. ten Hagen

Publisher
John Wiley and Sons
Year
1998
Tongue
French
Weight
98 KB
Volume
77
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

The blood residence half-life and organ distribution of recombinant human tumor necrosis factor-alpha (TNF-alpha) encapsulated in sterically stabilized liposomes, were investigated in rats bearing a soft tissue sarcoma in the hind leg. We studied the decay in blood concentration of "empty" liposomes using the aqueous marker 67gallium-desferal, as well as the blood concentration of soluble TNF-alpha and liposome encapsulated TNF-alpha using l25I. Encapsulation efficacy of TNF-alpha was 24%. The pharmacokinetics of TNF-alpha were markedly altered after encapsulation in liposomes, with a 33-fold increase in mean residence time of TNF-alpha in the blood, and a concomitant 14-fold increase in the area under the plasma concentration vs. time curve for liposomal TNF-alpha. Although the liposomes exhibit Stealth characteristics, uptake by mononuclear phagocyte-rich organs (e.g., liver and spleen) was noticeable, especially at later time points. Encapsulation of TNF-alpha in sterically stabilized liposomes resulted in a marked increase in localization of the cytokine in tumor measured as total uptake over time. However, peak TNF-alpha concentration levels in tumor were not significantly enhanced compared with free TNF-alpha. Besides the augmented localization of TNF-alpha after encapsulation in sterically stabilized liposomes, a diminished toxicity was observed.

📜 SIMILAR VOLUMES

Pegylated liposomal tumor necrosis facto
Pegylated liposomal tumor necrosis factor-α results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil®) in soft tissue sarcoma-bearing rats
✍ Timo L.M. ten Hagen; Ann L.B. Seynhaeve; Sandra T. van Tiel; Dirk J. Ruiter; Ale 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 337 KB

## Abstract Previously we reported that encapsulation of tumor necrosis factor‐α (TNF) in pegylated (STEALTH®) liposomes (TNF‐PEGL) dramatically improved circulation times of the protein and augmented accumulation in tumor tissue. We and others have demonstrated enhanced antitumor activity of doxor

Tumor necrosis factor-α augmented tumor
Tumor necrosis factor-α augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil®) correlates with altered Doxil® pharmacokinetics
✍ Peter Brouckaert; Nozomi Takahashi; Sandra T. van Tiel; Jeroen Hostens; Alexande 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 332 KB

## Abstract The application of tumor necrosis factor‐α (TNF) for the treatment of solid tumors is limited by its severe, life‐threatening, toxicity. Therefore, only low dosages of this cytokine can be applied systemically, which results in poor tumor response. It has been demonstrated previously th

Increased TIA-1 gene expression in the t
Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-α to patients with soft tissue limb sarcoma
✍ Simone Mocellin; Maurizio Provenzano; Mario Lise; Donato Nitti; Carlo Riccardo R 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB

## Abstract Although it is known that TNF‐α is effective in the treatment of advanced solid tumors such as melanoma and soft tissue sarcoma, the molecular mechanism underlying its anticancer activity remains unclear. Nineteen patients with locally advanced soft tissue sarcoma underwent isolated lim

Isolated limb perfusion with tumor necro
Isolated limb perfusion with tumor necrosis factor-α and melphalan for patients with unresectable soft tissue sarcoma of the extremities
✍ Eva M. Noorda; Bart C. Vrouenraets; Omgo E. Nieweg; Frits van Coevorden; Gooike 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

## Abstract ## BACKGROUND Since 1992, isolated limb perfusion (ILP) with tumor necrosis factor‐α (TNFα) and melphalan has been used for the treatment of patients with unresectable soft tissue sarcomas of the extremities. The authors retrospectively studied the results of limb salvage surgery using